Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089379 | 0.83 | ACHE (0.41) | TSHRLMNAACHESMN1; SMN2TDP1 | |
| SCHEMBL11108932 | 0.78 | TSHR (0.44) | TSHRCYP2C9HTTLMNAACHE | |
| SCHEMBL1758892 | 0.75 | CYP2C19 (0.41) | CYP2C9LMNACYP1A2GAAALDH1A1 | |
| SCHEMBL11302481 | 0.74 | ALDH1A1 (0.39) | HTTLMNAACHESMN1; SMN2ALDH1A1 | |
| SCHEMBL3278966 | 0.74 | ACHE (0.50) | TSHRCYP2C9HTTLMNAACHE | |
| SCHEMBL5255101 | 0.74 | TSHR (0.53) | TSHRCYP2C9HTTLMNASMN1; SMN2 | |
| SCHEMBL49632 | 0.73 | TSHR (0.43) | TSHRLMNAACHESMN1; SMN2CYP1A2 | |
| SCHEMBL92174 | 0.72 | ACHE (0.68) | TSHRCYP2C9HTTLMNAACHE | |
| SCHEMBL30167567 | 0.72 | ACHE (0.68) | TSHRCYP2C9HTTLMNAACHE | |
| SCHEMBL97030 | 0.71 | NCEH1 (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-4652648-A | STABILIZERS FOR HEAT, OXIDATION AND LIGHT | CIBA-GEIGY CORPORATION (US) | 1987-03-24 | — | — | US | disclosed |
| US-4579682-A | HEAT, OXYGEN, AND LIGHT PROTECTION FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0042359-B1 | PHOSPHONOUS-ACID MONOESTER MONOAMIDE AND ORGANIC POLYMERS STABILIZED THEREWITH | CIBA-GEIGY AG (CH) | 1984-10-31 | — | — | EP | disclosed |
| US-4434109-A | STABILIZERS AGAINST HEAT, OXYGEN AND LIGHT | CIBA-GEIGY CORPORATION (US) | 1984-02-28 | — | — | US | disclosed |
| EP-0042359-A1 | Phosphonous-acid monoester monoamide and organic polymers stabilized therewith | CIBA-GEIGY AG (CH) | 1981-12-23 | — | — | EP | disclosed |
| US-4259350-A | PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK | SANKYO COMPANY LIMITED (JP) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TSHR 319/4885CYP2C9 2351/4885HTT 4644/4885 |
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | TSHR 3439/4885CYP2C9 3609/4885HTT 4495/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | TSHR 110/4885CYP2C9 1680/4885HTT 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.